Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538260 | 0.91 | HDAC1 (0.64) | HDAC1SMN1; SMN2MAPTHPGDMEN1 | |
| SCHEMBL3538592 | 0.90 | HDAC1 (0.52) | HDAC1HPGDHDAC3HDAC2 | |
| SCHEMBL8263252 | 0.86 | HDAC1 (0.70) | HDAC1HDAC3HDAC2 | |
| SCHEMBL3534273 | 0.84 | HDAC1 (0.70) | HDAC1HDAC3HDAC2 | |
| SCHEMBL3534706 | 0.84 | HDAC1 (0.67) | HDAC1SMN1; SMN2MAPTHPGDL3MBTL1 | |
| SCHEMBL3537118 | 0.84 | HDAC1 (0.78) | HDAC1HDAC3HDAC2 | |
| SCHEMBL3539213 | 0.84 | HDAC1 (0.64) | HDAC1SMN1; SMN2MAPTHPGDMEN1 | |
| SCHEMBL3542409 | 0.82 | HDAC1 (0.64) | HDAC1HDAC3HDAC2 | |
| SCHEMBL3536619 | 0.81 | HDAC1 (0.60) | HDAC1SMN1; SMN2HDAC3HDAC2 | |
| SCHEMBL3535845 | 0.81 | HDAC1 (0.63) | HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | claimed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | claimed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1824831-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205941-A1 | Histone deacetylase inhibitors | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885SMN1; SMN2 3859/4885MAPT 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.